EW Q4 2023 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q4 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.3B-6.1% YoY

Gross Profit

$1.0B80.2% margin

Operating Income

$357M28.2% margin

Net Income

$370M29.2% margin

EPS (Diluted)

$0.61

QoQ Revenue Growth

+1.8%

Cash Flow

Operating Cash Flow

$137M

Free Cash Flow

$35M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$9.4B

Total Liabilities

$2.6B

Stockholders' Equity

$6.7B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$1.3B	-6.1%
Gross Profit	$1.0B	$1.1B	-3.5%
Operating Income	$357M	$410M	-12.9%
Net Income	$370M	$398M	-7.2%

Revenue Segments

Transcatheter Heart Valves

$979M64%

Critical Care

$251M16%

Surgical Heart Valve Therapy

$248M16%

Transcatheter Mitral And Tricuspid Therapies

$56M4%

Geographic Segments

UNITED STATES

$894M58%

Europe

$345M22%

Rest of World

$183M12%

JAPAN

$112M7%